Home / Conditions / Obesity (page 5)

Obesity

Obesity and Diabetes: Diabetes patients are considered obese when they have a Body Mass Index over 30. Such patients are at greater risk for a host of other problems cardiovascular disease, cancer, sleep apnea, and poor quality of life. Tremendous research is being done to control, manage, and reverse obesity in diabetics and the educated healthcare professional can help.

Can GLP‑1s Help Curb Alcohol Use? What Diabetes Clinicians Should Know

GLP-1 injection pen beside glasses of alcohol on a doctor's desk, representing potential alcohol use reduction benefits.

Early research suggests GLP‑1 drugs may reduce alcohol intake by dampening reward signaling and hedonic hunger, sparking interest among diabetes clinicians about the potential of GLP-1 alcohol use reduction. While findings so far are promising, understanding the nuances of the evidence is essential when talking with patients. This article explores …

Read More »

GLP‑1s and Sleep Apnea: A New Option for Treating Both Breathing and Blood Sugar

Man with sleep apnea using CPAP machine, surrounded by diabetes medications, glucose monitor, and lung illustration.

GLP‑1 receptor agonists have transformed the way we manage type 2 diabetes and obesity—but could they also play a role in sleep apnea treatment? The intersection of GLP-1 sleep apnea benefits is gaining attention, with new evidence suggesting these therapies may offer more than just weight loss. With diabetes and …

Read More »

GLP‑1s for Obesity: What Long‑Term Treatment Really Means for Diabetes Care

Doctor consulting an obese patient with GLP-1 medication pen, glucose monitor, and medical tools on desk, highlighting obesity and diabetes treatment.

The rise of GLP-1 obesity treatment has transformed how clinicians approach patients with both obesity and diabetes. These therapies, originally developed for glucose control, now show robust benefits in weight management. However, as use becomes more common in clinical practice, endocrinologists and primary care providers must balance glycemic outcomes, weight …

Read More »

Bridging the GLP‑1 Access Gap: Equity Strategies in a High‑Demand Era

Diverse healthcare team discussing GLP‑1 therapy access with medical tools and cost symbols in the foreground, illustrating treatment equity challenges.

As GLP‑1 drugs become more widely used for managing type 2 diabetes and obesity, concerns about access disparities have intensified. Unequal distribution and affordability threaten to create a two-tier healthcare system—where only those with greater means receive these life-changing therapies. In this article, we explore the concept of GLP‑1 access …

Read More »